U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron Pharmaceuticals (REGN) stock falls despite Q3 beat, a move attributed to lower-than-expected sales for its high-dose Eylea therapy. Read more here.

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Alvotech and Advanz Pharma’s ...

Regeneron Pharmaceuticals Inc (REGN) reports an 11% revenue increase, driven by DUPIXENT and EYLEA, while navigating pricing ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Narrow-moat Regeneron’s third-quarter results were in line with our expectations, thanks to resilient sales in the Eylea franchise and strong global sales of Sanofi and Regeneron’s immunology ...